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Abstract: Adrenocortical carcinomas (ACCs) with sarcomatous areas 
represent an extremely rare type of highly aggressive malignancy of 
unknown molecular pathogenesis. The current study was planned to gain 
insight into its molecular genetics using a targeted next-generation 
sequencing approach and to explore the status of epithelial-mesenchymal 
transition (EMT)-associated markers (E-/P-/N-Cadherins, MMP-2/-9 and 
Caveolin-1), downstream transcriptional regulators of EMT-related 
signaling pathways (ZEB-1/-2, Slug), stem cell factors (Oct3/4, LIN28, 
SOX2, SO17, NANOG, CD133, nestin) and markers of adrenocortical origin/ 
tumorigenesis (SF-1, β-catenin, p53) in phenotypically diverse tumor 
components of six cases. Thirteen pathogenic variants of ACC-associated 
TP53 and CTNNB1 genes were detected in epithelial and/or non-epithelial 
components in 4 out of 6 tumors. Three cases had identical mutations in 
distinct components, one of which containing TP53/CTNNB1 in 3 out of 5 
components, while one harbored a single TP53 mutation only in the non-
epithelial component. By immunohistochemistry, SF-1 and E-/P-/N-Cadherins 
were found positive only in the epithelial component of all cases, 
whereas the non-epithelial components were mainly enriched for nestin, 
ZEB-1 and MMP-2/-9. β-catenin demonstrated an aberrant nuclear 
localization in the sarcomatoid component of 5 cases, while p53 was 
strongly positive in non-epithelial constituent in 4 of 6 cases. In 
summary, we have shown that Wnt/β-catenin signaling pathway dysregulation 
and mutational inactivation of TP53 are common genetic events in 
sarcomatoid ACCs, a subset of which being monoclonal in origin. These 
tumors are enriched for EMT-related markers and stem cell factors, 
potentially conferring a poor prognosis, which might be exploited as 
novel therapeutic targets. 
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Letter of Submission
Dear Sir, 
 
 
Please find enclosed our manuscript entitled: Sarcomatoid Adrenocortical Carcinoma: A Comprehensive 
Pathological, Immunohistochemical and Targeted Next-Generation Sequencing Analysis, by Papathomas 
et al.  
 
We think this would be a study with high relevance to the endocrine pathology community and indeed the 
entire pathology community, as it unravels the unknown molecular pathogenesis of Adrenocortical 
carcinomas (ACCs) with sarcomatous areas, an extremely rare type of highly aggressive malignancy, by 
a targeted next-generation sequencing  (NGS) approach and an immunohistochemical investigation of 
epithelial-mesenchymal transition (EMT)-associated markers (E-/P-/N-Cadherins, MMP-2/-9 and 
Caveolin-1), downstream transcriptional regulators of EMT-related signaling pathways (ZEB-1/-2, Slug), 
stem cell factors (Oct3/4, LIN28, SOX2, SO17, NANOG, CD133, nestin) and markers of adrenocortical 
origin/ tumorigenesis (SF-1, β-catenin, p53) in phenotypically diverse tumor components of six cases.  
 
Highlights are summarized, as follows: 
 
(1) Wnt/β-catenin signaling pathway dysregulation is common genetic event in sarcomatoid ACCs 
 
(2) mutational TP53 inactivation is common genetic event in sarcomatoid ACCs 
 
(3) monoclonal evolution is displayed at least in a subset of sarcomatoid ACCs 
 
(4) sarcomatoid ACCs are enriched for EMT-related markers and stem cell factors  
 
We feel this paper would be of interest to the broad readership of your journal and would attract ample 
attention in the field of pathology and beyond. 
 
We are looking forward to hearing from you soon. 
 
Best Regards, 
Thomas Papathomas, M.D. 
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Dear Editor, 
 
First, I would like to thank you for your interest our manuscript number YHUPA-D-16-00233 entitled  
“Sarcomatoid Adrenocortical Carcinoma: A Comprehensive Pathological, Immunohistochemical and Targeted 
Next-Generation Sequencing Analysis’’ 
 
In this context, I would like to state with regard to the Editor comments, as annotated in red: 
 
Editors: 
 
1. The references are generally limited to 35 total. Please choose between eliminating nonessential references or 
offering a rationale for exceeding the limit. Also, please update reference #35 when more information becomes 
available. 
 
(1) The reference #35 has been updated as suggested. 
(2) we kept the references despite the fact the limit is exceeded given our approach to provide a comprehensive 
review of all reported sarcomatoid ACCs and a required body of the literature refering not only to similar molecular 
techniques, but also to immunohistochemical investigations on EMT and stem cell factors. We feel that in this way 
our current research work is additionally highlighted and strengthened. 
 
2. Please condense abstract to meet our 250-word limit. 
 
This is now amended (word count 247). 
 
3. Please note that the highlights should consist of only 3-5 bulleted key points, each no more than 85 characters. 
Please condense the highlights provided. More information can be found here: http://www.elsevier.com/journal-
authors/highlights. 
 
This is now amended, as follows: 
*Response to Reviewers
(1) Wnt/β-catenin signaling pathway dysregulation is common genetic event in sarcomatoid ACCs 
 
(2) mutational TP53 inactivation is common genetic event in sarcomatoid ACCs 
 
(3) monoclonal evolution is displayed at least in a subset of sarcomatoid ACCs 
 
(4) sarcomatoid ACCs are enriched for EMT-related markers and stem cell factors  
 
4. The addition of author degrees, conflict of interest disclosure and a running head (condensed version of full title 
limited to 60 characters) on the title page would be helpful. 
 
This is now amended in Pages 1-3. 
 
5. Please use superscript letters not symbols to label table footnotes. 
 
This is now amended in all tables. 
 
6. Consider adding magnification information to figure legends where appropriate. 
 
Given that all figures have been extracted from scanned virtual slides, the magnification information has been 
automatically preserved at the left bottom of each figure. 
 
Second, I would like to point out all of the amendments according to the valuable Reviewer 2 comments as 
annotated in red: 
 
1. The authors are advised to mention the proportion of sarcomatoid component in ACC and demonstrate by H&E 
staining the border between these two components, sarcomatoid and epithelial. 
 
(1) In all unpublished cases (n=3), the sarcomatoid component is estimated >10%; this is now amended in Table 1; 
nevertheless, the exact quantification is dependent on extensive sampling; when confronted with such large tumours 
is very challenging to sample the tumour in its entirety and hence accurately quantify the diverse components. 
(2) This is now illustrated in Figure 2. 
 
2. Figures. Even with the better quality, the images of H&E staining is too low in magnification and very hard to 
observe details. The authors are advised to demonstrate the H&E images of higher power as "Insets". 
 
This is now amended for both Figures. 
 
3. In the cases of mixed adeno-neuroendocrine carcinoma (MANEC) in neuroendocrine neoplasms (NEN), the same 
mutation of p53 gene was noted in both neuroendocrine carcinoma and adenocarcinoma, which suggested the 
monoclonal origin for both components. As a reference, the authors may include Neuroendocrinology 
2014,100:310-316. PMID: 25342539 
 
Given the limitatations concerning the number of references and as we exceeded the limit, we feel uncomfortable to 
add this reference. 
 
We would really appreciate if our latest revised version is taken into your precious consideration and looking 
forward to hearing from you soon. 
 
On behalf of all authors,  
Thomas Papathomas MD, PhD 
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 112 
Abstract 113 
 114 
Adrenocortical carcinomas (ACCs) with sarcomatous areas represent an extremely rare type of highly 115 
aggressive malignancy of unknown molecular pathogenesis. The current study was planned to gain 116 
insight into its molecular genetics using a targeted next-generation sequencing approach and to explore 117 
the status of epithelial-mesenchymal transition (EMT)-associated markers (E-/P-/N-Cadherins, MMP-2/-9 118 
and Caveolin-1), downstream transcriptional regulators of EMT-related signaling pathways (ZEB-1/-2, 119 
Slug), stem cell factors (Oct3/4, LIN28, SOX2, SO17, NANOG, CD133, nestin) and markers of 120 
adrenocortical origin/ tumorigenesis (SF-1, β-catenin, p53) in phenotypically diverse tumor components of 121 
six cases. Thirteen pathogenic variants of ACC-associated TP53 and CTNNB1 genes were detected in 122 
epithelial and/or non-epithelial components in 4 out of 6 tumors. Three cases had identical mutations in 123 
distinct components, one of which containing TP53/CTNNB1 in 3 out of 5 components, while one 124 
harbored a single TP53 mutation only in the non-epithelial component. By immunohistochemistry, SF-1 125 
and E-/P-/N-Cadherins were found positive only in the epithelial component of all cases, whereas the 126 
non-epithelial components were mainly enriched for nestin, ZEB-1 and MMP-2/-9. β-catenin 127 
demonstrated an aberrant nuclear localization in the sarcomatoid component of 5 cases, while p53 was 128 
strongly positive in non-epithelial constituent in 4 of 6 cases. In summary, we have shown that Wnt/β-129 
catenin signaling pathway dysregulation and mutational inactivation of TP53 are common genetic events 130 
in sarcomatoid ACCs, a subset of which being monoclonal in origin. These tumors are enriched for EMT-131 
related markers and stem cell factors, potentially conferring a poor prognosis, which might be exploited as 132 
novel therapeutic targets.  133 
 134 
 135 
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 137 
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 149 
Introduction 150 
 151 
Adrenocortical carcinomas (ACCs) with sarcomatous areas represent an extremely rare type of 152 
malignancy being the least common ACC variant following oncocytic and myxoid ACCs in decreasing 153 
order of frequency [1]. As a matter of fact, only 16 cases have been previously published, all of which as 154 
single case reports [2-17]. ACCs with sarcomatous areas have been variably designated 155 
carcinosarcomas or sarcomatoid carcinomas due to the presence of a specialized mesenchymal 156 
component, including osteosarcomatous, chondrosarcomatous or rhabdomyosarcomatous differentiation, 157 
or devoid of specific differentiation, respectively [2-17]. Nonetheless, this variant is characterized by a 158 
highly aggressive biologic behaviour and a worse prognosis in comparison with its conventional 159 
counterparts [1]. The question whether this aggressive clinical course may be attributed not only to 160 
advanced stage at presentation, but also to inherent biologic properties, still remains unanswered. 161 
Epithelial-mesenchymal transition (EMT) is a key developmental program that can be aberrantly activated 162 
during tumor progression, endowing cells with invasive and migratory properties, inducing stem cell 163 
properties, preventing apoptosis and senescence and contributing to chemo-resistance and 164 
immunosuppression [18]. During tumor progression, epithelial cells are driven towards a mesenchymal 165 
state, which subsequently enables them to evade hostile microenvironments generated by hypoxia, 166 
mechanical constraints and/or nutrient deprivation [19]. In this context, it has been shown that the 167 
induction of EMT endows breast epithelial cells with stem cell traits [20], while these EMT-derived cells 168 
share similarities with mesenchymal stem cells in terms of gene expression, multilineage differentiation, 169 
and ability to migrate towards tumor cells and wound sites [21]. Despite these lines of experimental 170 
evidence implying a link between EMT and cancer stem cells (CSCs), it still remains unsettled whether 171 
CSCs derive from EMT-induced differentiated cancer cells or from transformed tissue-specific stem cells 172 
[22]. Immunohistochemical expression of EMT markers has been documented in sarcomatoid 173 
carcinomas/carcinosarcomas [23-25], implying a potential role for EMT in such tumors. 174 
The purpose of the current study was to gain insight into the molecular genetics of this rare ACC variant 175 
by using a targeted next-generation sequencing (NGS) approach. In addition, we investigated the 176 
expression of EMT-associated markers, downstream transcriptional regulators of EMT-related signaling 177 
pathways and stem cell factors in morphologically diverse tumor components of sarcomatoid ACCs.  178 
 179 
 180 
 181 
 182 
6 
 
Materials & Methods 183 
Case series  184 
Six sarcomatoid ACCs were collected from five Departments of Pathology, three of which had previously 185 
been reported from the clinico-pathological viewpoint [8-9, 11]. Detailed clinico-pathological data of all 186 
cases included in the current study are summarized in Table 1. All cases were reviewed by two 187 
investigators (TP/ED) to identify the sarcomatoid areas. The study received ethical approval from the local 188 
Institutional Review Boards. 189 
Tissue preparation and immunohistochemistry (IHC)  190 
Sections serial to those used for conventional hematoxylin-eosin were obtained from one or two 191 
representative formalin-fixed paraffin-embedded (FFPE) blocks. The following markers were evaluated: (i) 192 
general ones of adrenocortical origin and differential diagnosis: pan-cytokeratin AE1/AE3, vimentin, 193 
Steroidogenic Factor 1 (SF-1), melan A, α-inhibin, synaptophysin, chromogranin A, neuron specific 194 
enolase (NSE), CD56 & Ki-67; (ii) markers involved in ACC tumorigenesis: β-catenin & p53; (iii) EMT-195 
related markers: E-Cadherin, P-Cadherin, N-Cadherin, Matrix-Metalloproteinases (MMP)-2, MMP-9 & 196 
Caveolin-1; (iv) downstream transcriptional regulators of EMT-related signaling pathways: ZEB1, ZEB2 & 197 
Slug; (v) stem cell factors: Oct3/4, LIN28, NANOG, SOX2, SOX17, CD133 & nestin. Antibodies 198 
employed, experimental conditions, staining interpretation and scoring systems are detailed in 199 
Supplementary Table 1. 200 
Adrenal cortical tumor series  201 
To investigate the specificity of those immunohistochemical markers expressed in sarcomatoid ACCs, i.e. 202 
EMT-related markers (N-Cadherin, P-Cadherin, E-Cadherin, MMP2, MMP9 and Caveolin-1), downstream 203 
transcriptional regulators of EMT-related signaling pathways (ZEB1) and stem cell factors (nestin, SOX2, 204 
SOX17 and LIN28), these were also assessed in 38 conventional ACCs and 17 adrenocortical adenomas 205 
(ACAs) (including 12 control tissue samples) arranged in a tissue microarray (TMA) format using an 206 
automated TMA constructor (ATA-27 Beecher Instruments, Sun Prairie, WI, USA; available at the 207 
Department of Pathology, Erasmus MC Cancer Institute) as previously described [26]. 208 
DNA Isolation  209 
From six sarcomatoid ACCs, 16 morphologically distinct tumour components (8 epithelial/ 8 sarcomatoid) 210 
were identified, as follows: 1 epithelial/1 sarcomatoid (cases No 1-2/4/6); 2 epithelial/ 3 sarcomatoid (case 211 
No 5); and 2 epithelial/ 1 sarcomatoid (case No 3). DNA isolation from 13 tumor areas (cases No 1-2/4-6) 212 
was carried out using standard procedures following manual microdissection. DNA isolation from the 213 
remaining 3 tumor areas (case No 3) following laser capture microdissection (Zeiss PALM Microbeam IV; 214 
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available at the Department of Pathology, Erasmus MC Cancer Institute). All tumor samples were 215 
estimated to contain at least 80% neoplastic cells. 216 
Targeted Next-Generation Sequencing (NGS) analysis  217 
Based on (i) mutations in ACCs, carcinosarcomas occurring at various anatomic locations, anaplastic 218 
thyroid carcinomas, and sarcomas; (ii) EMT-related pathways: Wnt pathway, MAPK pathway and 219 
PI3K/AKT pathway; and (iii) signalling pathways involved in the pathogenesis of adrenocortical tumors i.e. 220 
cAMP/PKA pathway, 18 genes were selected for mutational analysis: (1) APC (exons 12-14), (2) AXIN1 221 
(exons 1-6), (3) AXIN2 (exon 7), (4) CTNNB1 (exon 3), (5) BRAF (exons 11/15), (6) KRAS (exons 2-4), 222 
(7) NRAS (exons 2-4), (8) HRAS (exons 2-4), (9) EGFR (exons 18-21), (10) PI3KCA (exons 9/20), (11) 223 
AKT1 (exon 2), (12) AKT2 (exon 2), (13) AKT3 (exon 2), (14) PTEN (exons 3-5/7), (15) ALK (exons 23-224 
25), (16) ERBB2 (exons 19-20), (17) PRKAR1a (exons 4-8) and (18) TP53 (exons 2-11).  225 
An Ion AmpliSeq Custom Panel was created and sequenced on the Ion Torrent Personal Genome 226 
Machine (PGM; Life Technologies) on 10 nanograms (per sample) of FFPE tumor DNA according to the 227 
manufacturer’s protocols. In short, libraries were made using the Ion AmpliSeq Library Preparation Kit. 228 
Template was prepared using the Ion OneTouch Template Kit and sequencing was performed with the 229 
Ion Sequencing Kit v2.0 on an Ion 318 chip. 230 
Data were analyzed with Torrent Suite Software, version 3.6 (Life Technologies). Annotation of variant 231 
calls was performed with Annovar (http://www.openbioinformatics.org/annovar/) [27] and facilitated using 232 
an in-house galaxy platform/server on which Annovar wrapper was installed [28-30]. The variants (i) with 233 
a read frequency higher than 30%, (ii) not known as common polymorphisms according to 1000G2012 234 
April and ESP6500, (iii) non-synonymous with a minimum of 5 forward/ reverse variant read and 100 total 235 
depth read were retained as variants (mutations) and confirmed by alternate platforms i.e. Sanger direct 236 
sequencing. Sequences of all primers and probes are available upon request. 237 
TERT promoter mutation analysis  238 
In two cases displaying identical mutations in morphologically diverse components, hotspot TERT 239 
promoter mutations were analyzed by a SNaPshot assay using the ABI Prism SNaPshot Multiplex Kit 240 
(Applied Biosystems, Foster City, CA, USA) as previously described [26].  241 
Statistical analysis 242 
Non-parametric tests (Wilcoxon rank sum test) were used to study differences of immunohistochemical 243 
expression between the sarcomatoid series and control ACAs and conventional ACCs. Reciprocal 244 
correlations among the different expression of immunohistochemical markers among control ACCs and 245 
ACAs were made using a two-tailed Spearman’s test. 246 
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Results 247 
Clinical and pathological features of sarcomatoid ACCs  248 
Three unpublished cases analyzed herein further added to the existing body of the literature; thus 249 
accounting for 19 cases (Supplementary Table 2). Sarcomatoid ACCs are rare tumors characterized by 250 
a wide age range (23-79 years; median age 55; mean age 53.89) and no gender or laterality predilection. 251 
These are usually non-functioning tumors of large size (average 14cm; range 6.5cm up to 24cm). 252 
Microscopically, they predominantly display a pure spindle cell component (n=11), which can be 253 
occasionally admixed with foci of rhabdomyosarcomatous or osteosarcomatous differentiation or 254 
undifferentiated PNET-like areas (n=3). Less frequently a pure specialized mesenchymal component i.e. 255 
rhabdomyosarcomatous (n=3), osteosarcomatous (n=1) and osteosarcomatous/chondrosarcomatous 256 
constituents (n=1), can be detected. These are highly aggressive neoplasms with a high propensity for 257 
metastatic and/or recurrent disease and an average post-operative survival of 6.9 months. Two cases 258 
developed a second primary malignancy and associated metastatic disease. 259 
Immunohistochemical profile of sarcomatoid ACCs  260 
SF-1 was the sole adrenocortical marker positive in the epithelial component of all cases, but always 261 
negative in sarcomatoid areas. Cytokeratin AE1/AE3 was negative in all cases except for a focal positivity 262 
in the epithelial component of case No 1 and the sarcomatoid part of cases No 3 and 6. Conversely, 263 
vimentin was positive in both components of all cases, except for the epithelial component of case No 2. 264 
Neuron specific enolase had always a positive reactivity, while synaptophysin was positive in the 265 
epithelial component of four cases. Ki-67 proliferation index as estimated in the epithelial areas had a 266 
median value of 28% (range 1%-54%). β-catenin showed an aberrant nuclear localization in the 267 
sarcomatoid component of all but one case (No 2). β-catenin and p53 immunohistochemical data are 268 
summarized in Table 2 (Figure 1). 269 
Expression and/or specificity of EMT-related markers, downstream transcriptional regulators of 270 
EMT-related signaling pathways and stem cell factors in sarcomatoid ACCs  271 
Cadherins were positive only in the epithelial component. In particular, E- and P-cadherins were always 272 
negative except for case No 2; N-cadherin was negative in all components of cases No 1-2 and positive 273 
only in epithelial components of the other cases. Conversely, MMP-2 and/or MMP-9 were positive in 274 
sarcomatoid areas of all cases. ZEB-1 immunoreactivity/ ZEB-2 immunonegativity were noted in both 275 
components of all cases. Slug and Caveolin-1 were positive in the sarcomatoid component of five and 276 
four cases, respectively. Among stem cell markers, nestin was positive in sarcomatoid areas of all cases, 277 
while SOX-2, SOX-17 and LIN28 were positive in the sarcomatoid component of four, one and three 278 
cases, respectively. OCT3/4, NANOG and CD133 were always negative (Table 3). 279 
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Comparing the immunohistochemical expression of those markers demonstrated in sarcomatoid areas of 280 
sarcomatoid ACCs with a control series of conventional ACCs, MMP-2 and MMP-9 were found 281 
significantly more often expressed in sarcomatoid areas (Wilcoxon rank test, p<0.0001 and p=0.0002 282 
respectively), while ZEB1 was always positive in sarcomatoid components and mostly negative in 283 
conventional ACCs (Wilcoxon rank test, p=0.003). ACAs had a significant positive expression of N-284 
cadherin and P-cadherin as compared to ACCs (p<0.0001), while ZEB-1 and Caveolin-1 were 285 
significantly expressed in ACCs rather than in ACAs (p<0.0001). ACA stained mostly positive for N-286 
cadherin and P-cadherin (p<0.0001 for both markers). ZEB1 was always absent in ACA (p=0.005), while 287 
Caveolin 1 was positive in the majority of ACC (p<0.0001). 288 
Mutational analysis of sarcomatoid ACCs  289 
Targeted NGS revealed 13 pathogenic, nonsynonymous, variants of ACC-associated genes in epithelial 290 
and/or non-epithelial components in 4 out of 6 tumors. Three cases had identical mutations in 291 
phenotypically diverse components, one of which containing TP53/CTNNB1 in 3 out of 5 components, 292 
whereas one case harbored a single TP53 mutation in the non-epithelial component (Table 2). 293 
The epithelial and sarcomatoid tumor components displayed concordant p53 expression patterns in 5 out 294 
of 6 cases. However, the aberrant p53 expression pattern, i.e. loss of expression, could not be entirely 295 
explained by p53 mutations in the exons examined. Aberrant nuclear β-catenin expression, as detected in 296 
all but one sarcomatoid components, was the result of CTNNB1 mutations only in case No 5 (Table 2). 297 
No TERT promoter mutations were detected in four phenotypically diverse samples from two cases 298 
harboring TP53 or TP53/CTNNB1 mutations, respectively.  299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
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Discussion 310 
Adrenocortical carcinomas (ACCs) with sarcomatous areas are rare tumors of unknown molecular 311 
pathogenesis with respect to associated genetic alterations and potential clonal relationships between the 312 
phenotypically diverse tumor components. Herein, we provide novel mutational findings and molecular 313 
evidence of monoclonal origin. In addition, we elucidate the immunohistochemical profile as well as 314 
mechanisms potentially conferring such a highly aggressive biological behavior to these rare tumor 315 
variants, which are enriched for EMT-related markers and stem cell factors. 316 
The shared presence of TP53 and CTNNB1 gene mutations in both the epithelial and sarcomatoid 317 
compartments supports a common clonal origin at least in a subset of sarcomatoid ACCs. This is 318 
consistent with various molecular genetic studies, i.e. targeted NGS, mutational analysis, cytogenetic 319 
analysis, comparative genomic hybridization (CGH) analysis, as well as microdissection-based 320 
allelotyping/ loss of heterozygosity (LOH) analysis, in primary cutaneous carcinosarcomas [31-32], 321 
hepatic carcinosarcoma [33-34], maxillary carcinosarcoma [35] carcinosarcomas of the female genital 322 
tract [36-37], breast carcinosarcomas [38-39] and/or metaplastic breast carcinomas [40-41], salivary 323 
gland carcinosarcomas [42-43], sarcomatoid urothelial carcinomas of the urinary bladder [44-46], 324 
pharyngeal carcinosarcomas [44], esophageal carcinosarcomas [47], and pulmonary carcinosarcomas 325 
[48]. 326 
Three tumors harbored TP53 mutations both in epithelial and non-epithelial constituents indicating that 327 
these mutations are early driver events in their pathogenesis most likely predisposing tumor cells to 328 
acquire additional genetic aberrations that might activate other critical signaling pathways for this 329 
particular sarcomatous differentiation lineage. One CTNNB1 mutation concurred with a TP53 mutation in 330 
three morphologically diverse tumor components of a single tumor (case No 5). This finding further 331 
reinforces a previously proposed association between the status of the TP53 and CTNNB1 genes in 332 
adrenocortical tumorigenesis, based on either co-occurences of these mutations or CTNNB1 gains in 333 
advanced ACCs [49]. Likewise, aberrant nuclear β-catenin localization was observed in all TP53-mutated 334 
sarcomatous components as well as in all APC-mutated tumor components of case No 3.  335 
By using topographic genotyping with a targeted NGS technique combined with immunohistochemical 336 
investigation of EMT-related and stem cell-like markers, we tried to elucidate aspects of the molecular 337 
histogenesis of the sarcomatoid ACCs (Supplementary Figure 1). Notably, prior studies in 338 
carcinosarcomas, using a targeted NGS approach [33], microsatellite markers [47-48] or through deep 339 
sequencing [50] highlighted the complexity of the evolutionary process supporting either a continuous 340 
genetic progression model or a branched clonal divergent model with or without subclonal progression. 341 
By immunohistochemistry, we observed a downregulation of Cadherin expression along with an 342 
enrichment of various EMT-related markers in sarcomatoid components, implying a potential role for EMT 343 
in a subset of sarcomatoid ACCs (Figure 2). Additionally, the sarcomatoid compartments of all cases 344 
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displayed Wnt pathway activation, as evidenced by aberrant nuclear and/or cytoplasmic β-catenin 345 
localization. This could be attributed either to CTNNB1/APC mutations or potentially to aberrations in 346 
other tumor suppressor genes related to the Wnt/β-catenin pathway and/or negative crosstalk between 347 
SF-1 and Wnt/β-catenin signaling [51-53]. Mutational inactivation of TP53, accompanied by p53 348 
overexpression, was also a common genetic event (4 out of 6 cases). Given the critical role of the Wnt 349 
pathway in EMT [54] and the interplay between a fail-safe program escape and EMT [55-56], these 350 
molecular aberrations might mediate an EMT process in a subset of sarcomatoid ACCs. These 351 
observations are in agreement with data from mutational and immunohistochemical investigations of 352 
metaplastic breast carcinomas [41, 57-58] and primary cutaneous carcinosarcomas [31]. 353 
Nestin expression was noted almost exclusively in the sarcomatoid components of all examined cases 354 
along with Wnt/β-catenin pathway deregulation. Four tumors displayed SOX2 co-expression in 355 
subpopulations of the sarcomatoid components and adjacent epithelial areas (transitional zones in cases 356 
No 1 & 5) indicative of an active ongoing process. Of note is that (i) β-catenin has been shown as an 357 
important binding partner of SOX2 and a regulator of its transcriptional activity in a subset of breast 358 
cancer cells [59]; (ii) an enhancer region on the nestin gene is dependent on SOX2 binding [60]; and (iii) a 359 
biologically significant linkage between nestin and SOX2 expression has been previously reported in 360 
human melanomas [61]. Moreover, nestin and/or SOX2 expression is enriched in various tumor types 361 
playing a potential role in cancer progession as well as conferring a poor prognosis [61-65]. Although it is 362 
unclear whether these participate in EMT [61, 66] or reflect a cancer stem cell phenotype [66], a 363 
molecular-driven multifaceted targeted approach (Wnt/β-catenin signalling pathway, EMT program-364 
associated molecules and nestin) seems to be of great therapeutic interest [64, 67-68]. 365 
EMT-associated markers were more significantly expressed in the sarcomatoid areas than in 366 
conventional ACCs (lacking sarcomatoid areas) adding further evidence for a role in its pathogenesis. 367 
Nestin immunoexpression was detected in 5 out of 38 ACCs (13.5%) and in none of ACAs examined 368 
(0%) as compared to other data of 13 out of 16 ACCs (81%) and 2 out of 20 ACAs (10%) [69]. In 369 
accordance with EMT-related zinc-finger transcription factor Snail immunoexpression in adrenocortical 370 
tumours [70], we detected significant differences in N-/P-Cadherin and ZEB1/Caveolin-1 expression 371 
between ACCs and ACAs. Further studies in larger cohorts are warranted to delineate the exact role of 372 
EMT in adrenocortical tumorigenesis. 373 
In summary, we have shown that Wnt/β-catenin signaling pathway dysregulation and mutational 374 
inactivation of TP53 are common genetic events in adrenal cancers having a sarcomatous component. 375 
Targeted NGS approach provided molecular evidence of monoclonal evolution at least in a subset of 376 
cases. The term “sarcomatoid ACC” seems more appropriate than carcinosarcoma or others to address 377 
such a rare and aggressive variant of ACC. These tumors were enriched in EMT-related markers and 378 
stem cell factors, potentially conferring a poor prognosis and being exploited as novel therapeutic targets.  379 
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Figure Legends 620 
 621 
Figure 1. H&E staining, β-catenin and p53 immunoexpression patterns in epithelial (e1 in A-C; e2 in D-F) 622 
and sarcomatoid components (s1 in G-I; s2 in J-L) of case No 5. All components harbored an identical 623 
CTNNB1 p.S45F mutation displaying nuclear β-catenin immunoreactivity, whereas only those containing 624 
TP53 p.R249W mutations demonstrated strong p53 immunopositivity. Please note that sarcomatoid 625 
component (s3) within the inferior vena cava, harboring CTNNB1 p.S45F and TP53 p.R249W mutations 626 
and exhibiting similar β-catenin/p53 immunoexpression patterns to (s2), is not included in the panel. 627 
 628 
Figure 2. Immunohistochemical profile of case No 4: Note MMP2 (A)/Caveolin-1 (C)/ Nestin (D) 629 
immunoreactivity only in the sarcomatoid component abutting uninvolved pancreatic parenchyma (*) in 630 
contrast to N-Cadherin (B) as expressed in the epithelial compartment. ZEB-1 (E) is expressed both in 631 
the epithelial and adjacent sarcomatoid areas (transitional zone). 632 
 633 
 Table 1. Clinicopathological data of sarcomatoid ACCs investigated in the present series 
 
Case # Sex/Age Location Symptoms Size / Weight Gross Appearance ACC 
component 
Sarcomatoid 
component 
Clinical Follow-up  Reference 
1 M/31 L Abdominal pain/ no 
endocrine dysfunction 
12 cm /  
620 g 
Cystic degenerative cut 
surface, necrosis, 
hemorrhage 
WS 8 Spindle cell 
 
Locoregional recurrence 
with infiltration of the 
splenic hilum (2 mo)  
3 months DOD 
Sturm  [8] 
2 F/75 L Abdominal pain/ no 
endocrine dysfunction 
15 cm Variegated cut surface with 
whitish-gray firm solid areas, 
extensive necrosis and cysts 
WS 7 Spindle cell Liver metastases  (3 mo) 
12 months DOD 
Coli  [9] 
3 F/23 L Occasional finding, 
syncronous rectal 
cancer in pregnancy/ no 
endocrine dysfunction 
14 cm Irregular gray surface, 
central cavity filled with 
mucinous material 
  WS 7 
a
 Osteosarcoma 
 
widespread metastatic 
disease 
b
 
 14 months DOD 
Bertolini [11] 
4 M/55 L Abdominal pain/ 
no endocrine 
dysfunction 
16 cm Whitish gray cut surface, 
necrosis, hemorrhage 
WS 9 
c
 Spindle cell 
d
 widespread abdominal 
metastatic disease 
4 months DOD 
 
This  
study 
5 F/70 R Abdominal pain, 
diarrhea/ 
no endocrine 
dysfunction  
15 cm Cystic cut surface; cysts 
filled with clotted blood and 
viable appearing gray-white 
to partly yellow-white 
parenchyma 
Firm calcific areas Extensive 
necrosis and hemorhage 
WS 8 
 
Osteosarcoma 
Spindle cell 
d, e
 
 
Liver metastasis (2 mo) 
Lung and bone  
metastases (5 mo)  
8 months 
f
 DOD 
This  
study 
6 M/52 R Abdominal pain, fatigue, 
malaise, weight loss/ 
no endocrine 
dysfunction  
24 cm/  
3020 g 
Solid and partially cystic cut 
surface. Multiple necrotic 
areas  
 
WS 5 Spindle cell 
d
 Liver metastasis (two 
months prior to surgical 
resection) 
 Pleural metastasis (4 mo)  
4.5 months 
f
 DOD 
This  
study 
Abbreviations: ACC, adrenocortical carcinoma; F, female; M, male; NE; not evaluated; L, left; R, right; WS, Weiss Score  
a
 a conventional ACC with adipocytic-like areas displaying MDM2 gene polysomy as detected by FISH (experimental details available upon request) co-existing with a metastatic rectal adenocarcinoma 
b
 given the synchronous occurrence of a rectal adenocarcinoma, it becomes difficult to define the exact origin of the metastatic foci; due to the histopathologically proven metastasis of the rectal cancer 
to the adrenal gland, the patient was treated as having metastatic rectal cancer and thus mitotane was not an option 
c this case was originally reported as pheochromocytoma, due to a pheochromocytoma-like component comprising medium-sized cells, displaying scant nuclear atypia and a weakly eosinophilic 
cytoplasm, arranged in a nested or trabecular pattern. The diagnosis was amended (sarcomatoid ACC) following consultation. 
d
 the sarcomatoid component is estimated approximately >10% of the total tumour extent 
e
 two phenotypically diverse spindle cell components were identified (Figure 1) 
f  
postoperative time of death; Cases 5/6 were both treated with surgical resection and mitotane 
 
 
 
 
 
 
 
Table(s)
Table 2. Summary of pathogenic variants as detected by targeted NGS approach & β-catenin/P53 IHC as evaluated in 16 morphologically distinct 
tumour components from 6 sarcomatoid ACCs 
 
Case # Pathogenic  
Mutations 
β-catenin 
IHC 
P53  
IHC 
1 (e) --- m nor 
1 (s) TP53 
c.973G>T p.G325X 
(exon 9) 
n & c + 
2 (e) --- m - 
2 (s) --- c - 
3 (e1) --- 
a
 n - 
3 (e2) --- 
a
 n - 
3 (s) --- 
a
 n - 
4 (e) TP53 
c.995T>G p.I332S 
(exon 10) 
m + 
4 (s) TP53 
c.995T>G p.I332S 
(exon 10) 
n + 
5 (e1) CTNNB1 
c.134C>T p.S45F 
(exon 3) 
TP53 
c.745A>T p.R249W 
(exon 7) 
n + 
5 (e2) CTNNB1 
c.134C>T p.S45F 
(exon 3) 
n & m - 
5 (s1) CTNNB1 
c.134C>T p.S45F 
(exon 3) 
n - 
5 (s2) CTNNB1 
c.134C>T p.S45F 
(exon 3) 
TP53 
c.745A>T p.R249W 
(exon 7) 
n & c + 
5 (s3) CTNNB1 
c.134C>T p.S45F 
(exon 3) 
TP53 
c.745A>T p.R249W 
(exon 7) 
n & c + 
6 (e) TP53 
c.743G>A p.R248Q 
(exon 7) 
m + 
6 (s) TP53 
c.743G>A p.R248Q 
(exon 7) 
n + 
Table(s)
    
Abbreviations: +, overexpression; -, loss of expression; c, cytoplasmic; e, epithelial component; IHC, immunohistochemistry; m, membranous; nor; normal; n, nuclear;  s, sarcomatoid component 
a
 known germline APC mutation [11] 
 
 
Table 3. Expression of EMT-related markers, downstream transcriptional regulators of EMT-related signaling pathways and stem cell factors as 
evaluated in selected phenotypically distinct tumour components from 6 sarcomatoid ACCs.  
 
 
Antibodies 
 
Case # 1  
[8] 
 
Case # 2  
[9] 
 
Case # 3  
[11] 
 
Case # 4 
 
 
Case # 5 
 
 
Case # 6 
 
 e 
 
s 
  
e 
 
s 
 
e2 
 
s 
 
e 
 
s 
 
e2 
 
s2 
 
e 
 
s 
 
E-Cadherin - - + - - - - - - - - - 
P-Cadherin    - a - + - - - - - - - - - 
N-Cadherin - - - - + - + - + -        + b - 
MMP-2 - - - + - + - + - + - + 
MMP-9 - + - + - - - + - + - + 
ZEB-1      - c + +/- +/- +/- +/- + + + + + + 
ZEB-2 - - - - - - - - - - - - 
SLUG +/- + - - + + +/- + - +/- - + 
Caveolin-1 - + - - - - - + - + - + 
OCT3/4 - - - - - - - - - - - - 
NANOG - - - - - - - - - - - - 
CD133 - - - - - - - - - - - - 
LIN28 + + - -    -  a    - a - - - +                 -  a + 
SOX2      - c + - - -   + d - -      - c + - + 
SOX17 - - - - - - - - - - - + 
Nestin     - c + - + + + - + - + - + 
Abbreviations: EMT, epithelial-mesenchymal transition; e, epithelial component;  s, sarcomatoid component 
a only cytoplasmic localization 
        b epithelial areas displayed also N-Cadherin immunonegativity 
        c other epithelial areas adjacent to sarcomatous areas (transitional areas) displayed immunoreactivity 
               d osteoblasts displayed immunoreactivity, while osteocytes immunonegativity  
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